| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Articles |
From the Pharmacological Institute, College of Medicine, National Taiwan University, Taipei.
Correspondence to F.N. Ko, Pharmacological Institute, College of Medicine, National Taiwan University, No. 1, Jen-Ai Rd, Section 1, Taipei, Taiwan.
Abstract We examined the binding properties and
mitogenic effects of U46619, using cultured vascular smooth
muscle cells (VSMCs), by ligand-binding assay, measuring
[3H]thymidine and [3H]leucine
incorporation, checking with flow cytometry, and counting the cell
number. The U46619-activated mitogenic
signal-transduction pathway was assessed by mea-suring formation of
inositol monophosphate (IP); [Ca2+]i;
mitogen-activated protein kinase (MAPK), MAPK kinase (MAPKK),
and p74raf-1 activities; and GTP-bound Ras. [3H]U46619
bound to cultured VSMCs from Wistar-Kyoto (WKY) rats at a single class
of site (Kd: 15.5±2.6 nmol/L). However, it
bound to VSMCs from spontaneously hypertensive rats (SHRs) at two
classes of sites (Kd: 2.3±0.6 nmol/L and
1.4±0.5 µmol/L). U46619 increased DNA and protein synthesis,
cell number, IP formation, [Ca2+]i, and MAPK
and MAPKK activities, with EC50 values close to its
Kd value for the low-affinity binding site in
VSMCs from SHR. Prostaglandin (PG) E2 and
PGF2
showed little of such mitogenic
effects. All these effects of U46619 were inhibited by SQ29548,
staurosporine, or pretreatment of VSMCs with phorbol
12-myristate 13-acetate for 24 hours. However, U46619
stimulation did not lead to a significant increase in the Ras-GTP
complex or p74raf-1 activity. In conclusion, the mitogenic
effect of U46619 appears to be mediated via the activation of
low-affinity thromboxane binding sites that trigger
phosphoinositide hydrolysis and activate the
MAPK pathway, leading to DNA synthesis and cell proliferation.
Key Words: thromboxane receptor mitogen-activated protein kinase vascular smooth muscle cell proliferation protein kinase C
This article has been cited by other articles:
![]() |
P. Gluais, J. Paysant, C. Badier-Commander, T. Verbeuren, P. M. Vanhoutte, and M. Feletou In SHR aorta, calcium ionophore A-23187 releases prostacyclin and thromboxane A2 as endothelium-derived contracting factors Am J Physiol Heart Circ Physiol, November 1, 2006; 291(5): H2255 - H2264. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Hinton, L. Mellow, A. J. Halayko, A. Gutsol, and S. Dakshinamurti Hypoxia induces hypersensitivity and hyperreactivity to thromboxane receptor agonist in neonatal pulmonary arterial myocytes Am J Physiol Lung Cell Mol Physiol, February 1, 2006; 290(2): L375 - L384. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. J. Weber and L. M. Markillie Regulation of Activator Protein-1 by 8-iso-Prostaglandin E2 in a Thromboxane A2 Receptor-Dependent and -Independent Manner Mol. Pharmacol., May 1, 2003; 63(5): 1075 - 1081. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Young, K. Mahboubi, A. Haider, I. Li, and N. R. Ferreri Cyclooxygenase-2 Is Required for Tumor Necrosis Factor-{alpha}- and Angiotensin II-Mediated Proliferation of Vascular Smooth Muscle Cells Circ. Res., April 28, 2000; 86(8): 906 - 914. [Abstract] [Full Text] [PDF] |
||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1997 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |